Renal - Prismocitrate
Device
BAXTER HEALTHCARE
Total Payments
$377,257
Transactions
66
Doctors
2
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $90,078 | 12 | 0 |
| 2021 | $3,400 | 2 | 1 |
| 2018 | $283,779 | 52 | 2 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $366,960 | 55 | 97.3% |
| Consulting Fee | $4,903 | 3 | 1.3% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $3,355 | 1 | 0.9% |
| Education | $1,700 | 1 | 0.5% |
| Travel and Lodging | $218.11 | 2 | 0.1% |
| Food and Beverage | $121.00 | 4 | 0.0% |
Payments by Type
Research
$366,960
55 transactions
General
$10,297
11 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Clinical Evaluation of Use of Prismocitrate 18 in Patients Undergoing Acute Continuous Renal Replacement Therapy -CRRT- - 1407004 | BAXTER HEALTHCARE | $173,678 | 0 |
| Clinical Evaluation of Use of Prismocitrate 18 in Patients Undergoing Acute Continuous Renal Replacement Therapy -CRRT- - 1407004 | Baxter Healthcare | $103,205 | 1 |
| Safety Evaluation of Prismocitrate 18 in Patients Receiving CRRT | Baxter Healthcare | $90,078 | 0 |
Top Doctors Receiving Payments for Renal - Prismocitrate
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Birmingham, AL | $363,910 | 54 |
| Ashita Tolwani | Nephrology | Birmingham, AL | $10,297 | 11 |
| , M.D | Nephrology | Pittsburgh, PA | $3,050 | 1 |
Ad
Manufacturing Companies
- Baxter Healthcare $196,683
- BAXTER HEALTHCARE $180,574
Product Information
- Type Device
- Total Payments $377,257
- Total Doctors 2
- Transactions 66
About Renal - Prismocitrate
Renal - Prismocitrate is a device associated with $377,257 in payments to 2 healthcare providers, recorded across 66 transactions in the CMS Open Payments database. The primary manufacturer is BAXTER HEALTHCARE.
Payment data is available from 2018 to 2024. In 2024, $90,078 was paid across 12 transactions to 0 doctors.
The most common payment nature for Renal - Prismocitrate is "Unspecified" ($366,960, 97.3% of total).
Renal - Prismocitrate is associated with 3 research studies, including "Clinical Evaluation of Use of Prismocitrate 18 in Patients Undergoing Acute Continuous Renal Replacement Therapy -CRRT- - 1407004" ($173,678).